Literature DB >> 18545156

Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.

Sharon A Riddler1, Xiuhong Li, James Otvos, Wendy Post, Frank Palella, Lawrence Kingsley, Barbara Visscher, Lisa P Jacobson, A R Sharrett.   

Abstract

BACKGROUND: Alterations in serum lipids and an increased risk of myocardial infarction have been associated with HIV-1 infection and its treatment.
METHODS: Lipoprotein subclasses were measured by nuclear magnetic resonance spectroscopy in frozen plasma samples from participants in the Multicenter AIDS Cohort Study. The effects of HIV-1 infection, antiretroviral therapy, and other factors on median particle concentrations were examined using quantile regression.
RESULTS: Fasted samples were tested from 1082 men, including 609 HIV-seronegative and 473 HIV-1-infected men. Compared with HIV-seronegative men, HIV-1-infected men on antiretroviral therapy had an atherogenic phenotype with higher numbers of very low density lipoprotein and small low-density lipoprotein particles and lower numbers of high-density lipoprotein and large low-density lipoprotein particles. HIV-infected, antiretroviral-naive men had significantly lower high-density lipoprotein and small low-density lipoprotein particle concentrations compared with the HIV-seronegative men. Among men on antiretroviral therapy, the atherogenic phenotype was most pronounced in men with a good clinical status.
CONCLUSION: Use of antiretroviral therapy in HIV-1-infected men was associated with an "atherogenic lipoprotein phenotype."

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545156     DOI: 10.1097/QAI.0b013e31817bbbf0

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 2.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 3.  Antiretroviral treatment interruptions and risk of non-opportunistic diseases.

Authors:  Kenneth A Lichtenstein
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

Review 4.  Cardiovascular implications from untreated human immunodeficiency virus infection.

Authors:  Jason V Baker; Jens D Lundgren
Journal:  Eur Heart J       Date:  2011-01-12       Impact factor: 29.983

5.  A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.

Authors:  Tracy R McKnight; Hikari A I Yoshihara; Lungile J Sitole; Jeffery N Martin; Francois Steffens; Debra Meyer
Journal:  Mol Biosyst       Date:  2014-11

6.  Management of dyslipidemia in HIV-infected patients.

Authors:  Carlos D Malvestutto; Judith A Aberg
Journal:  Clin Lipidol       Date:  2011-08

7.  High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Authors:  Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

8.  Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

Authors:  Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton
Journal:  Atherosclerosis       Date:  2009-05-13       Impact factor: 5.162

9.  Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

Authors:  Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

10.  HAART-associated dyslipidemia varies by biogeographical ancestry in the multicenter AIDS cohort study.

Authors:  Matthew J Nicholaou; Jeremy J Martinson; Alison G Abraham; Todd T Brown; Shehnaz K Hussain; Steven M Wolinsky; Lawrence A Kingsley
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.